|
448 Products |
| 448 Products |
|
1070 Diseases |  |
113911 News |  |
| «12...5859606162636465666768...11171118» |
- || pregabalin / Generic mfg., nortriptyline / Generic mfg.
Clinical, Journal: The Comparative Efficacy of Palmitoylethanolamide (PEA) With the Combination of Pregabalin and Nortriptyline on Post-extraction Trigeminal Neuropathy by Using Magnetic Resonance (MR) Neurography: A Randomized Clinical Trial. (Pubmed Central) - Mar 27, 2024
Palmitoylethanolamide significantly reduces pain scores with negligible side effects. Conclusion Palmitoylethanolamide helps in the reduction of mild to moderate pain of painful post-traumatic trigeminal neuropathy (PTTN) with minimal side effects, suggesting that it may be used where the use of the conventional drug is either contraindicated or not feasible.
- | Journal: Weak base drug-induced endolysosome iron dyshomeostasis controls the generation of reactive oxygen species, mitochondrial depolarization, and cytotoxicity. (Pubmed Central) - Mar 27, 2024
Atropine (anticholinergic), azithromycin (antibiotic), fluoxetine (antidepressant), metoprolol (beta-adrenergic), and tamoxifen (anti-estrogen) at pharmacologically and therapeutically relevant concentrations (1) de-acidified endolysosomes, (2) decreased Fe2+ levels in endolysosomes, (3) increased Fe2+ and ROS levels in cytosol and mitochondria, (4) induced mitochondrial membrane potential depolarization, and (5) increased cell death; effects prevented by the endocytosed iron-chelator deferoxamine. Weak-base pharmaceuticals induce lysosome-stress responses that may affect their safety profiles; a better understanding of weak-base drugs on Fe2+ interorganellar signaling may improve pharmacotherapeutics.
- || mirtazapine / Generic mfg.
PK/PD data, Journal: Erratum: Pharmacokinetics of a Single Transdermal Dose of Mirtazapine in Rhesus Macaques (Macaca mulatta). (Pubmed Central) - Mar 27, 2024
Weak-base pharmaceuticals induce lysosome-stress responses that may affect their safety profiles; a better understanding of weak-base drugs on Fe2+ interorganellar signaling may improve pharmacotherapeutics. No abstract available
- | memantine / Generic mfg.
Journal: Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease. (Pubmed Central) - Mar 27, 2024
The top-ranked amiridine-based compound 5d was also inspected by in silico to reveal the butyrylcholinesterase binding differences with its close structural analogue 5b. Our study provides insight into the discovery of novel amiridine-based drugs by broadening their target-engaged profile from cholinesterase inhibitors towards MTDLs with potential implications in AD therapy.
- | risperidone / Generic mfg.
Preclinical, Journal: Gynura procumbens and selected metabolites: Amelioration of depressive-like behaviors in mice and risperidone-induced hyperprolactinemia in rats. (Pubmed Central) - Mar 27, 2024
Among the EEGS selected metabolites, the combined effect of chlorogenic acid and trans-p-coumaric acid was found to be more effective than the action of each compound in isolation. Collectively, the findings indicate that EEGS and its selected metabolites offer promising antidepressant benefits while counteracting hyperprolactinemia.
- || Byetta (exenatide) / AstraZeneca, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Review, Journal: Targeting autophagy to counteract neuroinflammation: a novel antidepressant strategy. (Pubmed Central) - Mar 27, 2024
The regulation of the immune system and inflammation by autophagy may lead to the development or deterioration of mental disorders. This review highlights the role of autophagy and neuroinflammation in the pathophysiology of depression, sumaries the autophagy-targeting small moleculars, and discusses a novel therapeutic strategy based on anti-inflammatory mechanisms that target autophagy to treat the disease.
- | Trial completion date, Surgery: Laparoscopic Sleeve Gastrectomy Surgery and External Oblique Intercostal Block (clinicaltrials.gov) - Mar 26, 2024
P=N/A, N=60, Active, not recruiting, Sponsor: Ondokuz May?s University
This review highlights the role of autophagy and neuroinflammation in the pathophysiology of depression, sumaries the autophagy-targeting small moleculars, and discusses a novel therapeutic strategy based on anti-inflammatory mechanisms that target autophagy to treat the disease. Trial completion date: Dec 2023 --> May 2024
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion date, Trial primary completion date: Impact of Near-Infrared Vein Mapping on Outcomes and Satisfaction After Botox/Filler Treatment (clinicaltrials.gov) - Mar 26, 2024
P=N/A, N=60, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Dec 2023 --> May 2024 Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
- | midomafetamine (MDMA) / Multidisciplinary Association for Psychedelic Studies (MAPS)
Journal: Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA). (Pubmed Central) - Mar 26, 2024
Phase III trials suggest that MDMA is superior to antidepressant medications for treating PTSD. Now that MAPS has officially requested the Food and Drug Administration to approve MDMA as a treatment for PTSD, legal MDMA-assisted therapy may become available as soon as 2024.
- || Tavegil (clemastine) / GSK
Review, Journal: Recognizing Alzheimer's disease from perspective of oligodendrocytes: Phenomena or pathogenesis? (Pubmed Central) - Mar 26, 2024
We believe that OL dysfunction is one important pathogenesis of AD. Factors regulating OLs might be biomarkers for early diagnosis and agents stimulating OLs warrant the development of anti-AD drugs.
- | cisplatin / Generic mfg.
Retrospective data, Journal, Real-world evidence, CINV, Real-world: Retrospective analysis of real-world prescribing data for managing cisplatin-based chemotherapy-induced nausea and vomiting in China. (Pubmed Central) - Mar 26, 2024
The current study reveals suboptimal utilization of recommended antiemetic drugs for managing cisplatin-based HEC-induced nausea and vomiting in China. Improving the management of CINV is crucial, and these findings provide valuable insights into optimizing antiemetic drug practices.
- | Sediel (tandospirone) / Sumitomo Pharma, Pfizer
Journal: Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open-labeled randomized control trial. (Pubmed Central) - Mar 26, 2024
The combined therapy rapidly acts on VaDep comorbid with anxiety and somatic symptoms and significantly alleviates the anxiety and somatic symptoms. The plasma levels of 5-HT may serve as potential objective candidates in evaluating VaDep severity and the efficacy of the undertaken treatment regimen.
- | clozapine / Generic mfg.
Journal: Proof-of-concept evidence for high-density EEG investigation of sleep slow wave traveling in First-Episode Psychosis. (Pubmed Central) - Mar 26, 2024
In the patient who was tested longitudinally during effective clozapine treatment, slow wave density normalized, while traveling distance only partially recovered. These preliminary findings suggest that slow wave traveling could be employed in larger samples to detect cortical "dys-connectivity" at psychosis onset.
- | imipramine / Generic mfg.
Journal: Evidence that keratinocyte microvesicle particles carrying Platelet-activating factor mediate the widespread multi-organ damage associated with intoxicated thermal burn injury. (Pubmed Central) - Mar 26, 2024
These studies provide evidence for PAF-enriched MVP generated in skin, which then act upon the gut PAFR resulting in bacterial translocation as the mechanism for the multi-organ dysfunction associated with ITBI. Inasmuch as aSMase inhibitors are widely available, these studies could result in effective treatments for ITBI.
- || Resolor (prucalopride) / J&J, Takeda
Retrospective data, Review, Journal, Surgery: Prucalopride and Bowel Function Post Gastrointestinal Surgery: Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Mar 26, 2024
Current RCT evidence suggests that prucalopride may enhance postoperative return of bowel function. Larger RCTs assessing patient important outcomes and associated costs are needed before routine use of this agent.
- | olanzapine / Generic mfg.
Preclinical, Journal: Olanzapine Liquisolid Tablets Using Kolliphor EL with Improved Flowability and Bioavailability: In vitro and In vivo Characterization. (Pubmed Central) - Mar 26, 2024
There was a remarkable decrease in the number of boxes covered in the open field test. Kolliphor EL was found to be a potential non-volatile solvent that can be used to produce liquisolid tablets of OLZ with improved flow, compressibility, dissolution, and bioavailability.
- | Sediel (tandospirone) / Sumitomo Pharma, Pfizer
Preclinical, Journal: Neonatal hypoxia impairs serotonin release and cognitive functions in adult mice. (Pubmed Central) - Mar 26, 2024
All together, these data demonstrate that the development of 5-HT system function is vulnerable to moderate perinatal asphyxia. 5-HT hypofunction might in turn contribute to long-term cognitive impairment in adulthood, indicating a potential target for pharmacological therapies.
- | olanzapine / Generic mfg.
Journal, CINV: Olanzapine for Chemotherapy-induced Nausea and Vomiting Pediatric Population: Take Home Message? (Pubmed Central) - Mar 26, 2024
5-HT hypofunction might in turn contribute to long-term cognitive impairment in adulthood, indicating a potential target for pharmacological therapies. No abstract available
- | clozapine / Generic mfg.
Journal: Electroanalytical characterization of clozapine at the electrified liquid-liquid interface and its detection in soft and hard drinks. (Pubmed Central) - Mar 26, 2024
Next, the electrochemical profiles of various soft and hard drinks were studied at the eLLI. The eLLI-based CZ sensor has shown a broad dynamic range (15-150 ?M), lower detection limits (1?M), and adequate reliability towards rapid CZ screening in spiked soft and hard drink samples with reference to the standard chromatographic analysis.
- | olanzapine / Generic mfg.
Preclinical, Journal: Allyl isothiocyanate, A TRPA1 agonist, protects against olanzapine-induced hypothalamic and hepatic metabolic aberrations in female mice. (Pubmed Central) - Mar 26, 2024
Furthermore, several of these effects were absent in the presence of HC-030031 (TRPA1 antagonist) indicating protective role of TRPA1 agonism in attenuating olanzapine-induced metabolic alterations. Supplementary in-depth studies are required to study TRPA1 channel effect on other aspects of olanzapine-induced metabolic alterations.
- | lactulose / Generic mfg., ondansetron / Generic mfg.
Journal: Mechanisms underlying the laxative effect of lactulose: A randomized placebo-controlled trial showing increased small bowel water and motility unaltered by the 5-HT3 receptor antagonist, ondansetron. (Pubmed Central) - Mar 26, 2024
Lactulose increases SBWC and stimulates small bowel motility; however, unexpectedly it did not significantly alter colonic water content, suggesting its laxative effect is not osmotic but due to stimulation of motility. Ondansetron's lack of effect on intestinal water suggests its anti-diarrheal effect is not due to inhibition of secretion but more likely altered colonic motility.
- | buspirone/zolmitriptan (JM-010) / Bukwang Pharma
Journal: Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study. (Pubmed Central) - Mar 26, 2024
P2
Ondansetron's lack of effect on intestinal water suggests its anti-diarrheal effect is not due to inhibition of secretion but more likely altered colonic motility. In this proof-of-concept study, addition of buspirone/zolmitriptan to the patients' PD medication regimen significantly reduced dyskinesia severity without worsening motor function.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P4 trial: Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea (clinicaltrials.gov) - Mar 26, 2024
P4, N=30, Completed, Sponsor: Istanbul Training and Research Hospital
- || NP-101 / Novatek Pharma
Phase classification, Trial completion date, Trial primary completion date: BOSS-002: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. (clinicaltrials.gov) - Mar 26, 2024
P2, N=308, Recruiting, Sponsor: Novatek Pharmaceuticals
In this proof-of-concept study, addition of buspirone/zolmitriptan to the patients' PD medication regimen significantly reduced dyskinesia severity without worsening motor function. Phase classification: P2a/2b --> P2 | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- Viibryd (vilazodone) / AbbVie
High-Dose Vilazodone for the Treatment of Major Depressive Disorder: A Case Report () - Mar 25, 2024 - Abstract #AAPP2024AAPP_292;
- memantine / Generic mfg.
From Mute to Multilingual: Successful Treatment of Benzodiazepine-Refractory Chronic Catatonia with Memantine () - Mar 25, 2024 - Abstract #AAPP2024AAPP_291;
- clozapine / Generic mfg.
Exploring the Need for Weight Loss Interventions in Clozapine Patients at a Veterans Affairs Healthcare System (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_233;
- citalopram / Generic mfg., escitalopram / Generic mfg.
Evaluation of EKG Monitoring for Citalopram and Escitalopram (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_226;
- aripiprazole / Generic mfg.
Evaluation of Aripiprazole in the Treatment of Food Avoidant Behaviors among Adolescents with Anorexia Nervosa (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_223;
- clozapine / Generic mfg.
Effect of Clozapine for Depressive Symptoms in Black Patients with Schizophrenia or Schizoaffective Disorders (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_215;
- duloxetine / Generic mfg.
Duloxetine for Treatment Resistant Depression in Older Adults (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_214;
- Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck
Comparison of Treatment Outcomes in the Veteran Population Administered Aripiprazole Long-acting Injectable Versus Paliperidone Palmitate Long-acting Injectable for Bipolar Disorder in the Inpatient Setting (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_212;
- Trintellix (vortioxetine) / Lundbeck, Takeda
Comparing the Cognitive Effect of Vortioxetine versus Other Selective Serotonin Receptor Inhibitors (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_209;
- clozapine / Generic mfg.
Clozapine, Caffeine, and Smoking: a Correlational Study and Initiation of Pharmacist?Led Interventions to Improve Clinical Outcomes (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_207;
- clozapine / Generic mfg.
Assessment of Clozapine Therapeutic Drug Monitoring (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_200;
- clozapine / Generic mfg.
Assessing Documentation of Clozapine Trials in Patients Prescribed Antipsychotic Polypharmacy Regimens at Discharge (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_198;
- trazodone ER / Generic mfg., fluoxetine / Generic mfg., quetiapine / Generic mfg.
Treatment Resistant Priapism in a 61-Year-Old Male After Combined Use of Trazodone, Quetiapine, and Fluoxetine. (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_188;
- Caplyta (lumateperone) - Intra / Cellular Therapies
Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_167;
- clozapine / Generic mfg.
Impacts of COVID-19 Events on Clozapine Therapeutics: A Case Report (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_160;
- risperidone / Generic mfg., paroxetine / Generic mfg.
Impact of Paroxetine 2D6 Inhibition in a Patient Transitioned From Oral Risperidone to Paliperidone Palmitate: A Case Report (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_157;
- Auvelity (bupropion/dextromethorphan) / Axsome Therap
Impact of AXS-05, an Oral NMDA Receptor Antagonist and Sigma-1 Receptor Agonist, on Anhedonic Symptoms in Major Depressive Disorder (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_154;
- Lybalvi (olanzapine/samidorphan) / Alkermes
Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_153;
- Auvelity (bupropion/dextromethorphan) / Axsome Therap
Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data From 3 Clinical Trials (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_135;
- Caplyta (lumateperone) - Intra / Cellular Therapies
Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for Treatment of Major Depressive Episodes Associated With Bipolar II Disorder (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_134;
- olanzapine / Generic mfg.
Comparison of High-Dose Olanzapine and Standard-Dose Olanzapine in Adult Patients at a County Psychiatric Hospital: A Retrospective Study (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_130;
- clozapine / Generic mfg.
Clozapine-Induced Neutropenia in the Management of Treatment-Resistant Schizophrenia: A Case Report (National BCD) - Mar 25, 2024 - Abstract #AAPP2024AAPP_128;
- clozapine / Generic mfg.
Practical Learnings and Knowledge When Implementing Rapid TDM Blood Levels: A Focus on Clozapine and Beyond () - Mar 25, 2024 - Abstract #AAPP2024AAPP_104;
Join us for a comprehensive session that bridges theory with practical applications in the field. Learning Objectives Understand key concepts in TDM Describe how to apply therapeutic range recommendations practically in patient management Outline how to utilize blood levels for clinical decision-making and treatment plan development
- fluvoxamine / Generic mfg., clozapine / Generic mfg.
The "Other Booster": Clozapine Augmentation with Fluvoxamine (IB II,virtual) - Mar 25, 2024 - Abstract #AAPP2024AAPP_85;
learning obejctive Review the role of clozapine and norclozapine levels in assessment of medication efficacy and tolerability. Identify appropriate clinical scenarios for utilizing fluvoxamine as an augmenting agent to clozapine.
- clozapine / Generic mfg.
Industry Showcase Practical Learnings and Knowledge When Implementing Rapid TDM Blood Levels: A Focus on Clozapine and Beyond (National A, Virtual) - Mar 25, 2024 - Abstract #AAPP2024AAPP_61;
It will cover how to practically apply therapeutic range recommendations in patient management, the role of norclozapine, how to integrate TDM with LAIs, and effective strategies for utilizing blood levels in clinical decision-making and treatment plan development. Join us for a comprehensive session that bridges theory with practical applications in the field.Learning Objectives Understand key concepts in TDM Describe how to apply therapeutic range recommendations practically in patient management Outline how to utilize blood levels for clinical decision-making and treatment plan development
- clozapine / Generic mfg.
Management of Clozapine-Resistant Schizophrenia (IB I, Virtual) - Mar 25, 2024 - Abstract #AAPP2024AAPP_53;
Identify evidence-based treatment strategies for clozapine-resistant schizophrenia. Evaluate different treatment options for clozapine-resistant schizophrenia.